Compare Pfizer with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ASTRAZENECA PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ASTRAZENECA PHARMA PFIZER/
ASTRAZENECA PHARMA
 
P/E (TTM) x 32.7 81.8 40.0% View Chart
P/BV x 5.5 23.0 23.8% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 PFIZER   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
ASTRAZENECA PHARMA
Mar-18
PFIZER/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,3651,278 185.1%   
Low Rs1,625883 184.1%   
Sales per share (Unadj.) Rs430.3228.4 188.4%  
Earnings per share (Unadj.) Rs78.710.4 759.4%  
Cash flow per share (Unadj.) Rs93.216.3 573.1%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs586.598.8 593.8%  
Shares outstanding (eoy) m45.7525.00 183.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.64.7 98.0%   
Avg P/E ratio x25.3104.2 24.3%  
P/CF ratio (eoy) x21.466.4 32.2%  
Price / Book Value ratio x3.410.9 31.1%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m91,27127,008 337.9%   
No. of employees `0002.61.4 194.0%   
Total wages/salary Rs m3,1431,535 204.7%   
Avg. sales/employee Rs Th7,484.84,210.9 177.7%   
Avg. wages/employee Rs Th1,195.01,132.2 105.5%   
Avg. net profit/employee Rs Th1,369.1191.1 716.5%   
INCOME DATA
Net Sales Rs m19,6855,710 344.7%  
Other income Rs m1,143123 933.0%   
Total revenues Rs m20,8285,833 357.1%   
Gross profit Rs m5,003463 1,080.8%  
Depreciation Rs m663147 449.5%   
Interest Rs m40-   
Profit before tax Rs m5,479438 1,250.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,878179 1,050.0%   
Profit after tax Rs m3,601259 1,389.7%  
Gross profit margin %25.48.1 313.5%  
Effective tax rate %34.340.8 83.9%   
Net profit margin %18.34.5 403.1%  
BALANCE SHEET DATA
Current assets Rs m24,1673,209 753.1%   
Current liabilities Rs m9,5442,070 461.2%   
Net working cap to sales %74.320.0 372.2%  
Current ratio x2.51.6 163.3%  
Inventory Days Days5572 76.2%  
Debtors Days Days2935 82.2%  
Net fixed assets Rs m9,514790 1,203.8%   
Share capital Rs m45850 915.0%   
"Free" reserves Rs m26,3752,419 1,090.2%   
Net worth Rs m26,8322,469 1,086.6%   
Long term debt Rs m250-   
Total assets Rs m36,9004,605 801.2%  
Interest coverage x1,305.5NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.51.2 43.0%   
Return on assets %9.85.6 173.6%  
Return on equity %13.410.5 127.9%  
Return on capital %20.417.7 115.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22300 7.5%   
Fx outflow Rs m1,4892,015 73.9%   
Net fx Rs m-1,466-1,715 85.5%   
CASH FLOW
From Operations Rs m3,31888 3,774.7%  
From Investments Rs m-2,383-94 2,545.9%  
From Financial Activity Rs m-1,104NA-  
Net Cashflow Rs m-169-6 2,956.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 75.0 85.2%  
Indian inst/Mut Fund % 7.5 0.3 2,500.0%  
FIIs % 4.9 15.7 31.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 9.1 260.4%  
Shareholders   85,207 12,856 662.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  GSK PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Oct 18, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS